Michael Kauffman - 24 Jul 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Director
Signature
/s/ Marc Belsky, Attorney-in-Fact
Issuer symbol
KZR
Transactions as of
24 Jul 2023
Net transactions value
$0
Form type
4
Filing time
26 Jul 2023, 17:04:18 UTC
Previous filing
16 Jun 2023
Next filing
16 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -8,896 -100% 0 24 Jul 2023 Common Stock 8,896 $7.63 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Award +8,896 8,896 24 Jul 2023 Common Stock 8,896 $2.28 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -8,896 -100% 0 24 Jul 2023 Common Stock 8,896 $5.60 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Award +8,896 8,896 24 Jul 2023 Common Stock 8,896 $2.28 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -26,000 -100% 0 24 Jul 2023 Common Stock 26,000 $5.59 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Award +26,000 26,000 24 Jul 2023 Common Stock 26,000 $2.28 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -26,000 -100% 0 24 Jul 2023 Common Stock 26,000 $4.80 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Award +26,000 26,000 24 Jul 2023 Common Stock 26,000 $2.28 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and exercisable.
F2 On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.